Most Read Articles
3 days ago
The phase III CASTOR and POLLUX studies previously demonstrated benefit of daratumumab plus bortezomib and dexamethasone (DVd) or lenalidomide and dexamethasone (DRd) vs standard-of-care (SoC) Vd or Rd regimen in relapsed or refractory multiple myeloma (R/R MM). The latest efficacy and safety results after 4 years of follow-up from CASTOR and POLLUX were presented at the American Society of Hematology (ASH) 61st Meeting & Exposition 2019 held in Orlando, Florida, US.  
Dr. Tai-Chung Lam, 3 days ago
While the armamentarium of therapies for metastatic non-small-cell lung cancer (NSCLC) has evolved to include various targeted therapies and immunotherapeutic agents, combinations with optimal efficacy and tolerability remain to be elucidated. At the 8th Joint Scientific Meeting of the Royal College of Radiologists (RCR) and Hong Kong College of Radiologists (HKCR) and 27th Annual Scientific Meeting of HKCR, Professor Tai-Chung Lam of the Department of Clinical Oncology, the University of Hong Kong, discussed the use of immunotherapy-based combinations for the management of EGFR-mutated NSCLC, with an emphasis on the role of the anti–PD-L1 antibody, atezolizumab. 
Dr. Jeff P. Sharman, 4 days ago
Acalabrutinib, used in combination with obinutuzumab or as monotherapy, improved progression-free survival (PFS) by 80–90 percent vs chlorambucil with obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia (CLL) in the phase III ELEVATE TN trial. The results, presented at the American Society of Haematology 61st Annual Meeting & Exposition (ASH 2019) by Dr Jeff P. Sharman of the Willamette Valley Cancer Institute and Research Center in Eugene, Oregon, US, demonstrated consistent PFS benefit across patient subgroups as well as tolerability of acalabrutinib therapy.

TTFields: A breakthrough modality for brain cancer treatment

Mr. William F. Doyle
Executive Chairman
Novocure Ltd.
09 Oct 2019
Mr Doyle on TTFields: A breakthrough modality for brain cancer treatment
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
The phase III CASTOR and POLLUX studies previously demonstrated benefit of daratumumab plus bortezomib and dexamethasone (DVd) or lenalidomide and dexamethasone (DRd) vs standard-of-care (SoC) Vd or Rd regimen in relapsed or refractory multiple myeloma (R/R MM). The latest efficacy and safety results after 4 years of follow-up from CASTOR and POLLUX were presented at the American Society of Hematology (ASH) 61st Meeting & Exposition 2019 held in Orlando, Florida, US.  
Dr. Tai-Chung Lam, 3 days ago
While the armamentarium of therapies for metastatic non-small-cell lung cancer (NSCLC) has evolved to include various targeted therapies and immunotherapeutic agents, combinations with optimal efficacy and tolerability remain to be elucidated. At the 8th Joint Scientific Meeting of the Royal College of Radiologists (RCR) and Hong Kong College of Radiologists (HKCR) and 27th Annual Scientific Meeting of HKCR, Professor Tai-Chung Lam of the Department of Clinical Oncology, the University of Hong Kong, discussed the use of immunotherapy-based combinations for the management of EGFR-mutated NSCLC, with an emphasis on the role of the anti–PD-L1 antibody, atezolizumab. 
Dr. Jeff P. Sharman, 4 days ago
Acalabrutinib, used in combination with obinutuzumab or as monotherapy, improved progression-free survival (PFS) by 80–90 percent vs chlorambucil with obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia (CLL) in the phase III ELEVATE TN trial. The results, presented at the American Society of Haematology 61st Annual Meeting & Exposition (ASH 2019) by Dr Jeff P. Sharman of the Willamette Valley Cancer Institute and Research Center in Eugene, Oregon, US, demonstrated consistent PFS benefit across patient subgroups as well as tolerability of acalabrutinib therapy.